Evotec AG (NASDAQ:EVTCY)‘s stock had its “sell” rating restated by DZ Bank AG in a report released on Thursday.

EVTCY has been the subject of a number of other research reports. Berenberg Bank reaffirmed a “buy” rating on shares of Evotec AG in a research report on Wednesday, May 10th. Deutsche Bank AG reissued a “neutral” rating on shares of Evotec AG in a report on Wednesday, May 3rd.

Evotec AG (NASDAQ EVTCY) traded up 5.68% during mid-day trading on Thursday, reaching $32.72. The company had a trading volume of 4,230 shares. The stock’s 50-day moving average price is $30.40 and its 200 day moving average price is $23.59. The firm has a market capitalization of $2.29 billion and a PE ratio of 54.72. Evotec AG has a 52 week low of $9.32 and a 52 week high of $33.30.

COPYRIGHT VIOLATION NOTICE: “Evotec AG’s (EVTCY) Sell Rating Reiterated at DZ Bank AG” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/evotec-ags-evtcy-sell-rating-reiterated-at-dz-bank-ag/1468548.html.

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.